Cancer Genetics (CGIX) Misses Q3 EPS by 7c

Cancer Genetics (NASDAQ: CGIX) reported Q3 EPS of ($0.56), $0.07 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.13 million.

For earnings history and earnings-related data on Cancer Genetics (CGIX) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c